Abstract 3936
Background
The Risk of Acute Deterioration (RAD) conceived as the patient status at risk for progression, with severe damage or life-threatening conditions, includes possible progression, emergence or recurrence of serious adverse-events Literature related with physiological parameters such blood pressure, cardiac or respiratory alterations and the capacity for a rapid identification of these RAD as predictors of preventable complications and adverse events The hematological patients with complex processes derived from his tumor, comorbidities and complexity hospitalized, may require admission to Iintensive care or unexpected death. Determine the patient profile that needs prevention and nursing activities and control for the risk of acute deterioration RAD at the centres of the Catalan Institute of Oncology-ICO, for 2018.
Methods
Retrospective multicenter cross-sectional study. Scope: 8 oncological units ICO-L’Hospitalet, ICO-Badalona and ICO-Girona. Data obtained from anonymized registries system of the electronic clinical history of patients.January to December of 2018.
Results
From 6.003 episodes of hospitalized patients, 2.661 contained an indicator of RAD as main nurse diagnostic on register, representing 44.3% of the cases. Observation and intensive surveillance or semi-intensive is fundamental. Nurses’ early identification of RAD and 39.06% needed intensive or semi-surveillance.Total deaths 10.68%. The registration of interventions: systematic control of mental state (77.09%); control of respiratory frequency in 29.14%; simultaneous recording of 5 vital signs (26.60%); 4 vital signs (82.16%); intake/out control (18.67%); record of diuresis (80.86%).
Conclusions
Nurses most performed and registered activities were control of heart rate, blood pressure, Sat. O2, temperature, diuresis and mind alert. Low registration for FR, despite being identified as a key intervention in the early identification of RAD and is omitted or is not registered although being prescribed in care plan. Early detection of physiological changes and the identification of patients RAD are need to provide adequate preventive care and treatment and to ensure continued evaluation that avoid deterioration or its consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract